Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 2Vasculitis 1Stomach Neoplasms 1Osteomyelitis 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Heart Diseases 1Head and Neck Neoplasms 1Fever of Unknown Origin 1Dementia 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × Tomography, Emission-Computed × Clear all
NCT01931709 2023-11-18

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

University of Washington

Phase NA Terminated
35 enrolled 11 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡